Scientech Research LLC Makes New $1.05 Million Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Scientech Research LLC bought a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the second quarter, Holdings Channel reports. The institutional investor bought 140,295 shares of the company’s stock, valued at approximately $1,052,000.

Other institutional investors have also modified their holdings of the company. Mubadala Investment Co PJSC acquired a new stake in Recursion Pharmaceuticals during the fourth quarter worth about $128,041,000. Capstone Investment Advisors LLC purchased a new stake in shares of Recursion Pharmaceuticals during the 1st quarter valued at approximately $161,000. Norges Bank purchased a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at approximately $34,825,000. UBS Group AG lifted its holdings in Recursion Pharmaceuticals by 101.9% in the fourth quarter. UBS Group AG now owns 691,911 shares of the company’s stock valued at $6,822,000 after acquiring an additional 349,232 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. grew its position in Recursion Pharmaceuticals by 6,439.6% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 169,900 shares of the company’s stock worth $1,274,000 after acquiring an additional 167,302 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Trading Down 2.6 %

NASDAQ:RXRX opened at $6.98 on Friday. The stock has a fifty day moving average price of $7.03 and a 200 day moving average price of $8.22. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 12-month low of $4.97 and a 12-month high of $15.74. The firm has a market cap of $1.96 billion, a PE ratio of -4.36 and a beta of 0.82.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The firm had revenue of $14.42 million during the quarter, compared to analyst estimates of $11.96 million. During the same period last year, the business earned ($0.38) EPS. The firm’s revenue was up 30.9% compared to the same quarter last year. Sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on RXRX shares. KeyCorp decreased their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Needham & Company LLC lowered their target price on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th. Jefferies Financial Group dropped their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday, September 3rd. Finally, Leerink Partners decreased their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $9.40.

Insider Activity

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $7.32, for a total transaction of $83,792.04. Following the sale, the director now owns 7,167,110 shares of the company’s stock, valued at $52,463,245.20. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CFO Michael Secora sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $6.17, for a total transaction of $92,550.00. Following the transaction, the chief financial officer now directly owns 1,377,756 shares in the company, valued at $8,500,754.52. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $7.32, for a total transaction of $83,792.04. Following the completion of the transaction, the director now directly owns 7,167,110 shares in the company, valued at $52,463,245.20. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 225,682 shares of company stock worth $1,590,044. 15.75% of the stock is currently owned by insiders.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.